Guy Weinberg Presents at EAPCCT
May 25, 2016
CHICAGO–(BUSINESS WIRE)–ResQ Pharma, Inc., a biopharmaceutical company focused on ensuring reliable, global use of LipidRescue™ Therapy (LRT), a treatment for various lipophilic drug overdoses & poisonings, today announced that Guy Weinberg, M.D., its co-founder and inventor of LRT will be presenting this Friday, May 27th at the Congress Of The European Association Of Poisons Centres And Clinical Toxicologists or EAPCCT in Madrid, Spain on advances in critical care of poisoned patients.
#Lipidrescue to treat acute poisonings: the fundamentals and the future @lipidguy #EAPCCT #CriticalCare #lifesaver
About Guy Weinberg, M.D.
Dr. Guy Weinberg is Perioperative Care Specialist with over 30 years of experience as an Anesthesiologist. He is currently a professor of Anesthesiology at the University of Illinois at Chicago College of Medicine and a staff member at Jesse Brown VA Medical Center. In addition, he serves on the board of directors of ResQ Pharma, Inc.
About LipidRescue™ Therapy (LRT)
LRT is ResQ Pharma’s lead product candidate which refers to the administration of a lipid emulsion with the intent of reducing the life-threatening clinical manifestations of toxicity from excessive doses of certain lipophilic drugs. It is already the opinion of the American Heart Association and American College of Medical Toxicology that where there is serious hemodynamic instability from local anesthetic drugs with high lipid solubility, LRT is a reasonable consideration for therapy, even if patient is not in cardiac arrest.
About ResQ Pharma
ResQ Pharma, Inc., is a biopharmaceutical company created to ensure reliable, global use of LRT, a treatment for various lipophilic drug overdoses & poisonings. For more information on ResQ Pharma, please visit www.LipidRescue.com. We are a member of iBIO’s PROPEL, EnterpriseWorks Chicago, Chicago Founders Circle, The BUNKER and MATTER! We are also a Qualified New Business Venture for the Illinois Investment Tax Credit Program.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future outcomes to identify these forward-looking statements. the ability and willingness of ResQ Pharma to continue research and development activities relating to LRT; our expectations regarding the clinical effectiveness and safety of our product candidates and results of studies; Any forward-looking statements in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after this press release.